---
name: sci-immune-modular-antibody-structure-function-mapping-4b9ba640
description: A reusable end-to-end workflow for mapping structure-function relationships in modular proteins and antibodies through boundary variants, recombinant partners, competition assays, and conformational analysis.
scienceevolve-title: "Antibody and immune recognition · modular antibody structure function mapping workflow"
scienceevolve-area: antibody-and-immune-recognition
---

## Purpose

Guide the decomposition of modular protein and antibody systems into candidate functional units, test the sufficiency of domain boundaries and recombinant partners, and iteratively refine structure-function hypotheses using orthogonal evidence and strong controls.

## When to use

- The research target is a modular protein complex, antibody, receptor-ligand module, or multi-domain recognition system.
- The goal is to identify minimal functional units, map domain boundaries, validate specificity, or distinguish direct interface effects from scaffold-dependent or conformational mechanisms.
- There are measurable functional readouts and structural or sequence information available, but the critical regions for recognition, stability, or partner compatibility are unknown.
- The user needs a non-clinical, non-operational research design framework rather than executable laboratory protocols.

## Inputs required

- Target system description: domain organization, available sequence or structural data, known binding partners, and functional readouts.
- Existing evidence: structural interfaces, conserved residues, mutation data, homology models, or prior binding data; note gaps explicitly.
- Perturbation space: candidate boundary variants, recombinant partner types, conformational states, or competitor molecules available for testing.
- Constraints: sample accessibility, ethical and safety boundaries, prohibited materials, and acceptable validation tiers.
- Research objective: a clearly defined mechanistic question (e.g., which region is necessary/sufficient for function, whether a partner is required for correct folding, or whether an effect is allosteric versus direct).

## Core Workflow

1. **Scope & Evidence Mapping**
   - Define the modular system, the candidate functional unit, and the specific structure-function gap.
   - Inventory existing evidence (structural, sequence, functional, dynamic) and classify each item as direct, indirect, or missing.
   - **Decision Gate**: Stop and redefine scope if the question is not mechanistically tractable or if no measurable readout exists.

2. **Competing Hypothesis Generation**
   - Generate at least three mechanistic hypotheses that could explain the observed or predicted function (e.g., direct interface sufficiency, scaffold/context dependence, allosteric propagation, conformational selection, non-specific artifact).
   - For each hypothesis, annotate: evidence strength (strong/moderate/weak), key assumptions, predicted discriminators (observations that would support or refute it), and failure modes.
   - **Decision Gate**: Refine hypotheses if they are not mutually distinguishable with available or attainable evidence.

3. **Minimal Validation Design**
   - Select perturbations: boundary variants (minimal core versus extended fragments), recombinant partner types, and conformational states.
   - Establish a control hierarchy: positive (known functional reference), negative (absence of target interaction), specificity (non-target or inactive variant), structural/conformational (folding and integrity checks), and quality (batch/background controls).
   - Define primary and orthogonal readouts, pre-registered success criteria, and stopping conditions.
   - **Decision Gate**: Redesign if the control hierarchy cannot disambiguate the leading hypotheses.

4. **Quality-First Analysis**
   - Verify sample integrity, identity, and conformational state before interpreting any functional readout.
   - Decompose readouts into specific signal versus background or artifact using the control hierarchy.
   - Populate a mechanism-evidence matrix that links each hypothesis to each experimental outcome (supports / weakens / inconclusive / artifact-risk).
   - **Decision Gate**: Halt functional interpretation if quality checks fail or controls behave anomalously; troubleshoot before proceeding to mechanistic claims.

5. **Iterative Convergence**
   - Compare observed outcomes against the predicted discriminators from Step 2.
   - Update each hypothesis: retain, modify, downgrade, or stop.
   - **Iteration / Stop Conditions**:
     - **Converge**: If a hypothesis is supported by two or more orthogonal evidence streams and is consistent with structural controls, advance to bounded claims and define extrapolation limits.
     - **Iterate**: If results are ambiguous, return to Step 2 or 3 to test refined boundary conditions, alternative partners, or additional conformational states.
     - **Stop**: Terminate if positive/negative controls fail, artifacts cannot be excluded, ethical or safety boundaries are reached, or further experiments no longer change hypothesis ranking. Report residual uncertainty.

6. **Structured Reporting**
   - Synthesize the research question, evidence map, hypothesis status, validation record, mechanism-evidence matrix, iteration log, and explicit claim boundaries into the output format.

## Output Format

Each invocation must produce:

1. **Research Question**: One sentence defining the modular structure-function problem.
2. **Evidence Map**: Known facts, indirect evidence, critical gaps, and non-extrapolable boundaries.
3. **Hypotheses**: 2–4 competing mechanisms, each with evidence strength, key assumptions, predicted discriminators, and failure modes.
4. **Minimal Validation Plan**: Perturbation set, control hierarchy, readouts, success criteria, and stop conditions.
5. **Analysis Plan**: Quality-first interpretation rules, mechanism-evidence matrix template, and signal/artifact separation strategy.
6. **Iteration Path**: Rules for upgrading, modifying, downgrading, or stopping hypotheses based on outcome categories.
7. **Validity and Safety Notes**: Confounding factors, reproducibility requirements, extrapolation boundaries, and ethical/safety limits.

## Validation Gates

- **Scope Gate**: The question is mechanistic, bounded, and testable with available readouts.
- **Hypothesis Gate**: Hypotheses are falsifiable and distinguishable via the planned evidence.
- **Design Gate**: The control hierarchy can disambiguate direct interface, scaffold, allosteric, and artifact explanations.
- **Quality Gate**: Sample integrity and control behavior are verified before any functional claim is made.
- **Convergence Gate**: Mechanistic claims require agreement between two or more orthogonal evidence streams and consistency with structural controls.
- **Boundary Gate**: Extrapolation limits are explicitly stated before conclusions are finalized.

## Claim Boundaries

- Claims are strictly bounded to the specific modular system, boundary variants, partners, and conditions tested.
- Do not extrapolate across protein families, species, or ligand types without additional validation.
- Distinguish observed association from mechanistic causation, and in vitro evidence from in vivo or clinical relevance.
- Do not present single-system observations as domain consensus.
- No clinical, diagnostic, or therapeutic conclusions may be drawn.

## Failure Modes

- **Hypothesis Failure**: The core interface is insufficient without neighboring scaffold regions; partner-dependent folding is required; conformational dynamics dominate over static interface geometry.
- **Experimental Failure**: Controls fail (positive, negative, or specificity); samples are impure, aggregated, or misfolded; readouts are saturated or below detection limits; batch effects obscure trends.
- **Interpretation Failure**: Confusing binding with function, correlation with causation, or specific signal with non-specific artifact; over-interpreting low-confidence structural models.
- **Iteration Failure**: Inability to converge due to insufficient orthogonal methods, unresolvable conformational heterogeneity, or safety/ethical limits preventing further perturbation.

## Validity Checks

- **Confounding**: Screen for impurities, degradation, aggregation, tag effects, surface or matrix effects, batch variation, and expression-level differences.
- **Specificity**: Verify target-dependent and partner-dependent behavior; use competition, saturation, and irrelevant-variant controls.
- **Reproducibility**: Require independent preparation and measurement, predefined exclusion criteria, and documented failure modes.
- **Statistical Rigor**: Predefine primary endpoints, report effect sizes and uncertainty, control for multiple comparisons, and separate exploratory from confirmatory analysis.
- **Structural Model Limits**: Treat models as constraining hypotheses, not proof; flag low-confidence loops, template bias, and missing regions.
- **Extrapolation**: Explicitly state boundaries for cross-system, cross-condition, or cross-species transfer; flag any inference that relies on homology alone.

## Provenance

- Synthesized from cluster 21 / subcluster 21.0.split0.
- Derived from source skills: `semisynthetic-antibody-domain-exploration`, `ace-antibody-structure-function-discovery`, `protein-interface-inhibition-exploration`, `antibody-affinity-dynamics-workflow`, `mucosal-antibody-assembly-research`, `antibody-fc-conformational-exploration-skill`, `4-1bb-co-stimulatory-receptor-exploration`, `igg-monocyte-binding-domain-exploration`.
- Representative of 31 skills in the modular antibody structure-function mapping cluster.
